UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549-1004
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE
OF REPORT (date of earliest event reported): APRIL 9, 2007
CIPHERGEN BIOSYSTEMS, INC.
(Exact name of Registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
000-31617
|
|
33-059-5156 |
| (State or other jurisdiction of
|
|
(Commission
|
|
(I.R.S. Employer |
| incorporation or organization)
|
|
File Number)
|
|
Identification Number) |
6611 Dumbarton Circle
Fremont, CA 94555
(Address of principal executive offices)
(510) 505-2100
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2.):
| o |
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (7 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On April 9, 2007, Ciphergen Biosystems, Inc. issued a press release announcing the receipt of
an audit opinion containing a “going concern” qualification. The press release is attached as
Exhibit 99.1 to this Form 8-K.
The information in this Current Report on Form 8-K is being furnished
and shall not be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) EXHIBITS.
| |
|
|
| EXHIBIT NO. |
|
DESCRIPTION |
| 99.1
|
|
Press release issued by Ciphergen Biosystems, Inc. on April 9,
2007 |